Device type · MAL
Graft, Vascular, Synthetic/Biologic Composite
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
MAL
Cardiovascular
Device class
Class II
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
14
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Graft, Vascular, Synthetic/Biologic Composite
- Product code
- MAL
- Device class
- Class II
- Review panel
- Cardiovascular
- Regulation
- 21 CFR 870.3450
- Specialty
- Cardiology
- FDA record
- Classification database entry for MAL
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
14
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
8
57% of reports
Injury reports
6
43% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 2 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 2 | 0 | 0 |
| Jun 24 | 0 | 1 | 0 | 0 |
| Jul 24 | 1 | 3 | 1 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 2 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 2 | 3 | 0 | 0 |
| May 25 | 0 | 1 | 0 | 0 |
| Jun 25 | 1 | 6 | 2 | 0 |
| Jul 25 | 2 | 2 | 0 | 0 |
| Aug 25 | 2 | 1 | 0 | 0 |
| Sep 25 | 2 | 2 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 1 | 1 | 0 | 0 |
| Feb 26 | 0 | 1 | 0 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 2 | 0 | 0 | 0 |
| May 26 | 0 | 2 | 0 | 0 |
| Jun 26 | 0 | 1 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 1 | 0 | 0 | 0 |
| Sep 26 | 1 | 0 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Product Quality Problem5
- Insufficient Device Problem Information3
- Material Puncture/Hole2
5 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions6
- Hemorrhage/Blood Loss/Bleeding4
- Bacterial Infection3
2 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0729-2022 · Started Jan 14, 2022
Reason given: Outer labelling (HEMASHIELD GOLD Knitted Microvel Double Velour Bifurcated Vascular Graft, D: 16 x 8 mm; L: 40 cm) does not correspond to the (inner) sterile packaging labelling (HEMASHIELD GOLD Knitted Microvel Double Velour Straight Vascular Graft, D: 7 mm L: 60 cm). Mislabeled product could cause a disruption of...
Cause as FDA categorized it: Packaging process control
Z-0403-2022 · Started Dec 1, 2021
Reason given: There is a probable mislabeling of product. A Hemashield Platinum Woven Double Velour Bifurcated Vasuclar Graft, SN 1259735369, 24 mm x 12 mm, REF Number M00202166241P0 is likely packaged inside of the carton instead of a Hemashield Gold Knitted Microvel Double Velour Bifurcated Vascular Graft; SN 1260004700; 18 mm x...
Cause as FDA categorized it: Labeling Change Control
Z-1859-2020 · Started Apr 7, 2020
Reason given: Potential small holes at the seam lines of Hemashield branches causing intra-operative bleeding at the seam lines of the branches of Hemashield grafts
Cause as FDA categorized it: Process design
46 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.